News
Video
Author(s):
Dr. Jacob Soumerai provides a comprehensive 5-year follow-up on the multicenter Phase II trial of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) in treatment-naïve chronic lymphocytic leukemia, highlighting sustained undetectable minimal residual disease rates, retreatment outcomes, and the prognostic significance of MRD kinetics (ΔMRD400).